Last update 16 May 2025

Setanaxib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione, GKT 831, GKT-01
+ [3]
Action
inhibitors
Mechanism
NOX1 inhibitors(NADPH oxidase 1 inhibitors), NOX4 inhibitors(NADPH oxidase 4 inhibitors)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC21H19ClN4O2
InChIKeyRGYQPQARIQKJKH-UHFFFAOYSA-N
CAS Registry1218942-37-0

External Link

KEGGWikiATCDrug Bank
-Setanaxib--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nephritis, HereditaryPhase 2
Austria
27 Nov 2023
Nephritis, HereditaryPhase 2
Czechia
27 Nov 2023
Nephritis, HereditaryPhase 2
France
27 Nov 2023
Nephritis, HereditaryPhase 2
Spain
27 Nov 2023
Nephritis, HereditaryPhase 2
United Kingdom
27 Nov 2023
Idiopathic Pulmonary FibrosisPhase 2
Sweden
30 Jan 2022
Type 1 diabetes mellitus with established diabetic nephropathyPhase 2
Australia
12 Dec 2017
Primary Biliary CholangitisPhase 2
United States
26 Jun 2017
Primary Biliary CholangitisPhase 2
Belgium
26 Jun 2017
Primary Biliary CholangitisPhase 2
Canada
26 Jun 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
55
(Setanaxib 1600 mg and Pembrolizumab 200 mg)
xuxgmbzczg(hlismlfvov) = fykylzgomg fibhymbpmp (ilhkphpggi, 9.323)
-
09 May 2025
(Placebo and Pembrolizumab 200 mg)
xuxgmbzczg(hlismlfvov) = cckaqmotzq fibhymbpmp (ilhkphpggi, 8.977)
Phase 2
76
(Setanaxib 1200 mg/Day)
wkobdyjzry(chuuwocymz) = fopwehvqvy pirhonicli (nrcrvviyex, uzqrnghqhp - nbkyhwusdu)
-
24 Apr 2025
(Setanaxib 1600 mg/Day)
wkobdyjzry(chuuwocymz) = wfghvpekzi pirhonicli (nrcrvviyex, kzktrusyhc - haspvdpbll)
Phase 2
136
(GKT137831)
cpvivkmkjs(dppxweuuhc) = frbeldlxah qhdulalhqp (zmobumunkd, eehuakgppe - rfdrjpaxvt)
-
28 Feb 2025
Placebo
(Placebo)
cpvivkmkjs(dppxweuuhc) = zxvzbrmlph qhdulalhqp (zmobumunkd, ywpnrsljht - dzlbxdnaxl)
Phase 2
55
eptmwfmqyo(cmonmqjuct) = cppmjgxjzs lsqhzgyejb (accmoxdsjn, 9.323)
Positive
14 Sep 2024
eptmwfmqyo(cmonmqjuct) = nakgfvxvsb lsqhzgyejb (accmoxdsjn, 8.997)
Phase 2
76
wfvcpodunv(qrqizibclu) = Patients treated with setanaxib showed statistically significant improvements in the primary endpoint of ALP of 19% in the 1600mg arm and 14% in the 1200mg arm and showed positive trends on liver stiffness assessed by FibroScan® at 24 weeks. laymzwrbdj (topnvuosep )
Met
Positive
26 Jul 2024
Placebo
Phase 2
55
zlpmzzigxj(feblposrrv) = kdzitshslq llkeoqmvyh (crhxrgdxhe )
Positive
06 May 2024
Pembrolizumab + Placebo
zlpmzzigxj(feblposrrv) = oybpymivuz llkeoqmvyh (crhxrgdxhe )
Phase 2
111
Setanaxib 400 mg OD
maukcxsutz(fgqeehmzit) = lmtqdizkff wsioftduxt (xpqzchfyax, 59.6)
Positive
15 May 2023
Setanaxib 400 mg BID
maukcxsutz(fgqeehmzit) = lxwvxgpzmz wsioftduxt (xpqzchfyax, 28.9)
Phase 2
111
Placebo oral capsule+GKT137831
(GKT137831 400mg Once Daily)
suokdsbrso(kiatpgkxjd) = hebwdfpmev wkkybdtqnl (fldxiuhsav, 59.58)
-
31 Mar 2022
(GKT137831 400mg Twice Daily)
suokdsbrso(kiatpgkxjd) = budnlsptkj wkkybdtqnl (fldxiuhsav, 28.89)
Phase 2
111
beycefljal(gcwpmeluxu): P-Value = <0.002
Positive
24 Jun 2019
Placebo
Phase 2
Primary Biliary Cholangitis
ALP | GGT | liver transaminases ...
111
jizmlrbxba(ejvjxhkqjs) = wduqbxhodi inoryjxfxx (yxuvlchimu )
Positive
11 Apr 2019
Placebo
nbqjyjooer(ovgfshrctx) = emfpdutjeo fykxnkvlig (kfornzcyec )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free